Literature DB >> 24792487

Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status.

Aaron J Lindsay1, Sarah Z Rush2,3, Laura Z Fenton4.   

Abstract

Ganglioglioma (GG) is a rare pediatric brain tumor (1-4 %) with neoplastic glial and neuronal cells. Posterior fossa GGs (PF GGs) occur less frequently than supratentorial GGs (ST GGs). The BRAF V600E mutation has been reported in GGs and carries therapeutic implications. We compare the presenting symptoms, magnetic resonance imaging, BRAF V600E mutation status, treatment, and prognosis in children with ST and PF GGs. The neuro-oncology database at a tertiary care Children's Hospital was retrospectively reviewed from 1995 to 2010 for patients with ST and PF GG. All available imaging was reviewed. Symptoms, BRAF V600E mutation status, treatment, and survival data were collected from the electronic medical record and analyzed. Our series consisted of 11 PF GG and 20 ST GG. Children with PF GG presented with ataxia, cranial nerve deficits and long tract signs whereas the majority with ST GGs presented with seizures. On imaging, PF GGs were infiltrative and expansile solid masses with dorsal predominant "paintbrush" enhancement whereas ST GGs were well circumscribed mixed solid and cystic masses with heterogeneous enhancement. Five of 11 (45%) PF GGs and 6 of 9 (67%) ST GGs expressed the BRAF V600E mutation. No unique imaging features were identified in BRAF V600E mutation positive tumors. The majority of ST GGs were treated with surgery alone, whereas the majority of PF GGs required multimodality therapy. PF GGs had worse progression-free survival and a higher mortality rate compared with ST GGs. Unlike ST GGs, PF GGs are expansile, infiltrative, show dorsal predominant "paintbrush" enhancement, are not amenable to gross total resection, and have worse progression-free survival and mortality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792487     DOI: 10.1007/s11060-014-1450-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

Review 1.  Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas.

Authors:  C S Rumana; A B Valadka
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Authors:  Margaret J Dougherty; Mariarita Santi; Marcia S Brose; Changqing Ma; Adam C Resnick; Angela J Sievert; Phillip B Storm; Jaclyn A Biegel
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

4.  Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery.

Authors:  So-Hyang Im; Chun Kee Chung; Byung-Kyu Cho; Kyu-Chang Wang; In-Kyu Yu; In Chan Song; Gi Jeong Cheon; Dong Soo Lee; Na-Rae Kim; Je G Chi
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

5.  Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.

Authors:  Céline Chappé; Laetitia Padovani; Didier Scavarda; Fabien Forest; Isabelle Nanni-Metellus; Anderson Loundou; Sandy Mercurio; Frédéric Fina; Gabriel Lena; Carole Colin; Dominique Figarella-Branger
Journal:  Brain Pathol       Date:  2013-03-20       Impact factor: 6.508

6.  Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.

Authors:  Andrew M Donson; Bette K Kleinschmidt-DeMasters; Dara L Aisner; Lynne T Bemis; Diane K Birks; Jean M Mulcahy Levy; Amy A Smith; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  Brain Pathol       Date:  2013-12-23       Impact factor: 6.508

7.  BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma.

Authors:  Sonika Dahiya; Devon H Haydon; David Alvarado; Christina A Gurnett; David H Gutmann; Jeffrey R Leonard
Journal:  Acta Neuropathol       Date:  2013-04-23       Impact factor: 17.088

8.  Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Otmar D Wiestler; Johannes Schramm
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

9.  Factors contributing to resectability and seizure outcomes in 44 patients with ganglioglioma.

Authors:  Young Seok Park; Dong-Seok Kim; Kyu-Won Shim; Jung-Hee Kim; Joong-Uhn Choi
Journal:  Clin Neurol Neurosurg       Date:  2008-05-21       Impact factor: 1.876

Review 10.  The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.

Authors:  Gholamreza Safaee Ardekani; Seyed Mehdi Jafarnejad; Larry Tan; Ardavan Saeedi; Gang Li
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

View more
  8 in total

1.  Ganglioglioma in children and young adults: single institution experience and review of the literature.

Authors:  Wafik Zaky; Shekhar S Patil; Minjeong Park; Diane Liu; Wei-Lien Wang; Khalida M Wani; Susana Calle; Leena Ketonen; Soumen Khatua
Journal:  J Neurooncol       Date:  2018-06-07       Impact factor: 4.130

Review 2.  High Resolution MRI of Vestibulocochlear Nerve Involvement by a Posterior Fossa Ganglioglioma: Case Report and Review of Literature.

Authors:  Bárbara Trapp; Charlie Chia-Tsong Hsu; Jyoti Panwar; Timo Krings
Journal:  Clin Neuroradiol       Date:  2018-06-01       Impact factor: 3.649

Review 3.  Pediatric infratentorial ganglioglioma.

Authors:  Stephanie Puget; Awad Alshehri; Kevin Beccaria; Thomas Blauwblomme; Giovanna Paternoster; Syril James; Federico Dirocco; Christelle Dufour; Michel Zerah; Pascale Varlet; Christian Sainte-Rose
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

4.  Relative ADC and Location Differ between Posterior Fossa Pilocytic Astrocytomas with and without Gangliocytic Differentiation.

Authors:  J H Harreld; S N Hwang; I Qaddoumi; R G Tatevossian; X Li; J Dalton; K Haupfear; Y Li; D W Ellison
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-28       Impact factor: 3.825

5.  Radiological Evaluation of Infratentorial Gangliogliomas in Various Anatomic Locations of the Cerebellum and Brainstem.

Authors:  S Zhang; L Ai; X Z Chen; K Wang
Journal:  Clin Neuroradiol       Date:  2016-01-07       Impact factor: 3.649

6.  Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma.

Authors:  Laflamme Philippe; Kondyli Maria; Aljared Tariq; Miconiatis Sofia; Saint-Martin Christine; Farmer Jean-Pierre; Roy W Dudley; Perreault Sébastien; Jabado Nada; Larouche Valérie
Journal:  J Neurooncol       Date:  2019-09-09       Impact factor: 4.130

7.  Identification of BRAF p. V600E-Mutant and Wild-Type by MR Imaging in Pleomorphic Xanthoastrocytoma and Anaplastic Pleomorphic Xanthoastrocytoma.

Authors:  W Huang; J Cai; N Lin; Y Xu; H Wang; Z Wu; D Kang
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-01       Impact factor: 3.825

Review 8.  Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.

Authors:  Saivenkat Vagvala; Jeffrey P Guenette; Camilo Jaimes; Raymond Y Huang
Journal:  Cancer Imaging       Date:  2022-04-18       Impact factor: 5.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.